Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26500623
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Front+Microbiol
2015 ; 6
(ä): 1077
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
New strategic insights into managing fungal biofilms
#MMPMID26500623
Borghi E
; Morace G
; Borgo F
; Rajendran R
; Sherry L
; Nile C
; Ramage G
Front Microbiol
2015[]; 6
(ä): 1077
PMID26500623
show ga
Fungal infections have dramatically increased in the last decades in parallel
with an increase of populations with impaired immunity, resulting from medical
conditions such as cancer, transplantation, or other chronic diseases. Such
opportunistic infections result from a complex relationship between fungi and
host, and can range from self-limiting to chronic or life-threatening infections.
Modern medicine, characterized by a wide use of biomedical devices, offers new
niches for fungi to colonize and form biofilm communities. The capability of
fungi to form biofilms is well documented and associated with increased drug
tolerance and resistance. In addition, biofilm formation facilitates persistence
in the host promoting a persistent inflammatory condition. With a limited
availability of antifungals within our arsenal, new therapeutic approaches able
to address both host and pathogenic factors that promote fungal disease
progression, i.e., chronic inflammation and biofilm formation, could represent an
advantage in the clinical setting. In this paper we discuss the antifungal
properties of myriocin, fulvic acid, and acetylcholine in light of their already
known anti-inflammatory activity and as candidate dual action therapeutics to
treat opportunistic fungal infections.
free
free
free
